Literature DB >> 24002447

Clot retraction is mediated by factor XIII-dependent fibrin-αIIbβ3-myosin axis in platelet sphingomyelin-rich membrane rafts.

Kohji Kasahara1, Mizuho Kaneda, Toshiaki Miki, Kazuko Iida, Naoko Sekino-Suzuki, Ikuo Kawashima, Hidenori Suzuki, Motoyuki Shimonaka, Morio Arai, Yoshiko Ohno-Iwashita, Soichi Kojima, Mitsuhiro Abe, Toshihide Kobayashi, Toshiro Okazaki, Masayoshi Souri, Akitada Ichinose, Naomasa Yamamoto.   

Abstract

Membrane rafts are spatially and functionally heterogenous in the cell membrane. We observed that lysenin-positive sphingomyelin (SM)-rich rafts are identified histochemically in the central region of adhered platelets where fibrin and myosin are colocalized on activation by thrombin. The clot retraction of SM-depleted platelets from SM synthase knockout mouse was delayed significantly, suggesting that platelet SM-rich rafts are involved in clot retraction. We found that fibrin converted by thrombin translocated immediately in platelet detergent-resistant membrane (DRM) rafts but that from Glanzmann's thrombasthenic platelets failed. The fibrinogen γ-chain C-terminal (residues 144-411) fusion protein translocated to platelet DRM rafts on thrombin activation, but its mutant that was replaced by A398A399 at factor XIII crosslinking sites (Q398Q399) was inhibited. Furthermore, fibrin translocation to DRM rafts was impaired in factor XIII A subunit-deficient mouse platelets, which show impaired clot retraction. In the cytoplasm, myosin translocated concomitantly with fibrin translocation into the DRM raft of thrombin-stimulated platelets. Furthermore, the disruption of SM-rich rafts by methyl-β-cyclodextrin impaired myosin activation and clot retraction. Thus, we propose that clot retraction takes place in SM-rich rafts where a fibrin-αIIbβ3-myosin complex is formed as a primary axis to promote platelet contraction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24002447     DOI: 10.1182/blood-2013-04-491290

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  What Is the Biological and Clinical Relevance of Fibrin?

Authors:  Rustem I Litvinov; John W Weisel
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

Review 2.  Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism.

Authors:  Rami A Al-Horani; Srabani Kar
Journal:  Eur J Med Chem       Date:  2020-05-18       Impact factor: 6.514

Review 3.  Fibrinogen and Factor XIII in Venous Thrombosis and Thrombus Stability.

Authors:  Alisa S Wolberg; Yaqiu Sang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-06-02       Impact factor: 10.514

Review 4.  Composition and Organization of Acute Ischemic Stroke Thrombus: A Wealth of Information for Future Thrombolytic Strategies.

Authors:  Jean-Philippe Desilles; Lucas Di Meglio; Francois Delvoye; Benjamin Maïer; Michel Piotin; Benoît Ho-Tin-Noé; Mikael Mazighi
Journal:  Front Neurol       Date:  2022-07-06       Impact factor: 4.086

5.  Ethacrynic acid is an inhibitor of human factor XIIIa.

Authors:  Srabani Kar; Kayla Vu; Madhusoodanan Mottamal; Rami A Al-Horani
Journal:  BMC Pharmacol Toxicol       Date:  2022-06-01       Impact factor: 2.605

6.  Kinetics and mechanics of clot contraction are governed by the molecular and cellular composition of the blood.

Authors:  Valerie Tutwiler; Rustem I Litvinov; Andrey P Lozhkin; Alina D Peshkova; Tatiana Lebedeva; Fazoil I Ataullakhanov; Kara L Spiller; Douglas B Cines; John W Weisel
Journal:  Blood       Date:  2015-11-24       Impact factor: 22.113

7.  Factor XIII in plasma, but not in platelets, mediates red blood cell retention in clots and venous thrombus size in mice.

Authors:  Sravya Kattula; James R Byrnes; Sara M Martin; Lori A Holle; Brian C Cooley; Matthew J Flick; Alisa S Wolberg
Journal:  Blood Adv       Date:  2018-01-03

8.  Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel.

Authors:  Rolf P Kreutz; Janelle Owens; Deshun Lu; Perry Nystrom; Yan Jin; Yvonne Kreutz; Zeruesenay Desta; David A Flockhart
Journal:  Platelets       Date:  2014-05-15       Impact factor: 3.862

9.  Dominant role of αIIbβ3 in platelet interactions with cross-linked fibrin fragment D-dimer.

Authors:  Lorena Buitrago; Hina Zafar; Yixiao Zhang; Jihong Li; Thomas Walz; Barry S Coller
Journal:  Blood Adv       Date:  2020-07-14

10.  Functional factor XIII-A is exposed on the stimulated platelet surface.

Authors:  Joanne L Mitchell; Ausra S Lionikiene; Steven R Fraser; Claire S Whyte; Nuala A Booth; Nicola J Mutch
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.